[go: up one dir, main page]

AR128267A1 - Derivados de azaindol y su uso como inhibidores de la erk-quinasa - Google Patents

Derivados de azaindol y su uso como inhibidores de la erk-quinasa

Info

Publication number
AR128267A1
AR128267A1 ARP230100088A ARP230100088A AR128267A1 AR 128267 A1 AR128267 A1 AR 128267A1 AR P230100088 A ARP230100088 A AR P230100088A AR P230100088 A ARP230100088 A AR P230100088A AR 128267 A1 AR128267 A1 AR 128267A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
compound
erk
alkyl group
Prior art date
Application number
ARP230100088A
Other languages
English (en)
Inventor
Cdric BORIES
Loc Mathieu
Jean Guichou
- Gelin Muriel Franois
Aurlien Biechy
Original Assignee
Agv Discovery
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agv Discovery, Inst Nat Sante Rech Med, Centre Nat Rech Scient, Univ Montpellier filed Critical Agv Discovery
Publication of AR128267A1 publication Critical patent/AR128267A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Compuesto de la fórmula (1) en donde: R¹ representa un grupo alquilo (C₁-C₆); R² representa un grupo alquilo (C₁-C₆), un grupo cicloalquilo (C₃-C₆), o un grupo alquilo (C₁-C₆) sustituido por uno o más radicales seleccionados de átomos de halógeno, grupo ciano, grupo alcoxi (C₁-C₆) y grupo cicloalquilo (C₃-C₆); o R¹ y R² forman junto con el átomo de nitrógeno un grupo heterocíclico de 3 a 6 miembros; R³, R⁴, R⁵, R⁶, R⁷, R⁸ y R⁹ representan, independientemente entre sí, un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo (C₁-C₆), un grupo trifluorometilo o un grupo ciano, en donde dicho grupo alquilo (C₁-C₆) está opcionalmente sustituido con un grupo alcoxi (C₁-C₆); o una de sus sales farmacéuticamente aceptables. Reivindicación 16: Compuesto de acuerdo con cualquiera de las reivindicaciones anteriores, para uso en la prevención y/o inhibición y/o tratamiento de una enfermedad o condición mediada por actividad de quinasas ERK, en particular por actividad de quinasas ERK2. Reivindicación 17: Compuesto para uso de acuerdo con la reivindicación 16, en donde la enfermedad o el estado se selecciona de cánceres y metástasis.
ARP230100088A 2022-01-14 2023-01-13 Derivados de azaindol y su uso como inhibidores de la erk-quinasa AR128267A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22305031.1A EP4212531A1 (en) 2022-01-14 2022-01-14 Azaindole derivatives and their use as erk kinase inhibitors

Publications (1)

Publication Number Publication Date
AR128267A1 true AR128267A1 (es) 2024-04-10

Family

ID=80445694

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100088A AR128267A1 (es) 2022-01-14 2023-01-13 Derivados de azaindol y su uso como inhibidores de la erk-quinasa

Country Status (14)

Country Link
US (2) US11827637B2 (es)
EP (2) EP4212531A1 (es)
JP (1) JP2025502377A (es)
KR (1) KR20240134887A (es)
CN (1) CN118541370A (es)
AR (1) AR128267A1 (es)
AU (1) AU2023207276A1 (es)
CA (1) CA3242894A1 (es)
CL (1) CL2024002070A1 (es)
CO (1) CO2024008809A2 (es)
IL (1) IL314199A (es)
MX (1) MX2024008629A (es)
TW (1) TW202334147A (es)
WO (1) WO2023135233A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
AU2024287893A1 (en) * 2023-07-12 2026-01-08 Agv Discovery Crystalline form of (s)-1-(1-(3-chlorophenyl)-2- (dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3- b]pyridin-3-yl)pyridin-2(1h)-one, its preparation and its use as erk kinase inhibitor
WO2025012357A1 (en) * 2023-07-12 2025-01-16 Ipsen Pharma Fluorinated azaindole derivatives and their use as erk kinase inhibitors
AU2024297019A1 (en) * 2023-07-12 2026-01-22 Agv Discovery Salts of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5- morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one, their preparation and their use as erk kinase inhibitors
EP4588918A1 (en) 2024-01-18 2025-07-23 AGV Discovery Synthesis of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)- 4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
ES2651439T3 (es) 2004-05-14 2018-01-26 Vertex Pharmaceuticals Incorporated Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN100396678C (zh) 2004-11-16 2008-06-25 财团法人工业技术研究院 1-苯甲基-3-(5’-羟甲基-2’-呋喃基)吲唑的吲哚类似物的合成及用途
CN101541783B (zh) 2006-06-30 2014-10-01 苏尼西斯制药有限公司 吡啶酮基pdk1抑制剂
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
WO2012094313A1 (en) 2011-01-04 2012-07-12 Kinentia Biosciences Llc Pyrazole derivatives as erk inhibitors
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CN104755478B (zh) 2012-10-16 2017-10-10 霍夫曼-拉罗奇有限公司 丝氨酸/苏氨酸激酶抑制剂
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
KR20170103838A (ko) 2015-01-23 2017-09-13 컨플루언스 라이프 사이언시스, 인코포레이티드 염증 및 암의 치료를 위한 헤테로시클릭 itk 저해제
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
EP4424320A3 (en) 2016-12-09 2025-06-11 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
AU2019381808A1 (en) * 2018-11-16 2021-05-27 1200 Pharma Llc ERK inhibitors and uses thereof
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors

Also Published As

Publication number Publication date
CN118541370A (zh) 2024-08-23
IL314199A (en) 2024-09-01
JP2025502377A (ja) 2025-01-24
CL2024002070A1 (es) 2024-11-29
KR20240134887A (ko) 2024-09-10
US12421231B2 (en) 2025-09-23
EP4212531A1 (en) 2023-07-19
WO2023135233A1 (en) 2023-07-20
US20240308997A1 (en) 2024-09-19
AU2023207276A1 (en) 2024-08-01
CA3242894A1 (en) 2025-02-28
EP4463453A1 (en) 2024-11-20
TW202334147A (zh) 2023-09-01
MX2024008629A (es) 2024-08-19
US11827637B2 (en) 2023-11-28
US20230227451A1 (en) 2023-07-20
CO2024008809A2 (es) 2024-08-08

Similar Documents

Publication Publication Date Title
AR128267A1 (es) Derivados de azaindol y su uso como inhibidores de la erk-quinasa
AR093580A1 (es) Inhibidores bmi-1 de pirimidina sustituidos
AR095430A1 (es) Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr
CO6231028A2 (es) Compuestos y composiciones como inhibidores de la proteina quinasa
TR200401903T4 (tr) Raf kınaz tesir önleyici olarak imidazol-2-karboksamid türevleri.
RU2017105781A (ru) Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение
AR117978A1 (es) Inhibidores de 15-pgdh
AR093468A1 (es) Derivados de piridina
AR048427A1 (es) Derivados de sulfonilpirroles con actividad inhibitoria de la histona deacetilasa, composiciones farmaceuticas que los contienen y el uso de las mismas para el tratamiento de enfermedades relacionadas.
AR119971A1 (es) Derivados de piridazin-3(2h)-ona fusionados con azol
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
AR124048A1 (es) Inhibidores de la btk
AR119910A1 (es) DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL
AR097755A1 (es) Derivados sustituidos de fenilalanina como moduladores del factor xia
AR115965A1 (es) Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática
AR129339A1 (es) Inhibidores de parg
AR089853A1 (es) Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
AR116400A1 (es) Compuesto de imidazopiridinona
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AR125117A1 (es) Actividad antiviral de inhibidores de vps34
AR122103A1 (es) Derivados de cinolina con actividad herbicida
AR069028A1 (es) Derivados de 1,2,4-triazol pirrolidina fusionados como moduladores de mglur5
AR119340A1 (es) DERIVADOS DE TIENO[3,2-b]PIRIDIN-2-CARBOXAMIDA COMO MODULADORES DEL RECEPTOR DE NMDA
AR122336A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
AR119199A1 (es) Compuestos para el tratamiento de trastornos neuromusculares